Stryker Corporation $SYK Stock Position Lifted by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. raised its stake in Stryker Corporation (NYSE:SYK) by 6.0% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 170,867 shares of the medical technology company’s stock after buying an additional 9,640 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Stryker were worth $67,759,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. FineMark National Bank & Trust increased its stake in shares of Stryker by 17.5% in the second quarter. FineMark National Bank & Trust now owns 4,846 shares of the medical technology company’s stock worth $1,917,000 after acquiring an additional 723 shares during the last quarter. Primecap Management Co. CA boosted its position in Stryker by 16.1% during the second quarter. Primecap Management Co. CA now owns 504,762 shares of the medical technology company’s stock valued at $199,699,000 after purchasing an additional 69,912 shares during the last quarter. Aspen Investment Management Inc grew its stake in Stryker by 4.1% in the second quarter. Aspen Investment Management Inc now owns 5,127 shares of the medical technology company’s stock valued at $2,028,000 after purchasing an additional 202 shares in the last quarter. Wealthspire Advisors LLC increased its position in Stryker by 112.5% in the 2nd quarter. Wealthspire Advisors LLC now owns 11,958 shares of the medical technology company’s stock worth $4,731,000 after purchasing an additional 6,332 shares during the last quarter. Finally, Perennial Investment Advisors LLC increased its position in Stryker by 4.9% in the 2nd quarter. Perennial Investment Advisors LLC now owns 1,099 shares of the medical technology company’s stock worth $435,000 after purchasing an additional 51 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Activity

In other news, Director Ronda E. Stryker sold 276,173 shares of the company’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the transaction, the director owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. This represents a 9.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO William E. Berry, Jr. sold 1,953 shares of the company’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $365.49, for a total value of $713,801.97. Following the completion of the transaction, the chief accounting officer directly owned 2,833 shares of the company’s stock, valued at approximately $1,035,433.17. This trade represents a 40.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 522,453 shares of company stock valued at $185,516,867. 5.90% of the stock is owned by company insiders.

Stryker Price Performance

NYSE SYK opened at $359.53 on Wednesday. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19. The company has a fifty day simple moving average of $370.62 and a 200 day simple moving average of $381.03. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The company has a market cap of $137.49 billion, a P/E ratio of 47.62, a P/E/G ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last released its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. The firm had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, sell-side analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on SYK shares. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a research note on Thursday, September 18th. Truist Financial increased their price target on shares of Stryker from $392.00 to $400.00 and gave the stock a “hold” rating in a research note on Friday, November 14th. Rothschild & Co Redburn started coverage on shares of Stryker in a research note on Thursday, September 18th. They issued a “neutral” rating and a $420.00 price objective for the company. Finally, UBS Group set a $408.00 price objective on shares of Stryker in a report on Monday, October 13th. Thirteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $434.37.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.